VIR logo

VIR
Vir Biotechnology Inc

6,340
Mkt Cap
$1.04B
Volume
1.29M
52W High
$9.98
52W Low
$4.16
PE Ratio
-2.06
VIR Fundamentals
Price
$7.47
Prev Close
$7.71
Open
$7.79
50D MA
$6.66
Beta
1.54
Avg. Volume
1.99M
EPS (Annual)
-$3.83
P/B
1.30
Rev/Employee
$181,875.00
$103.21
Loading...
Loading...
News
all
press releases
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate update and discuss its financial...
Business Wire·5d ago
News Placeholder
More News
News Placeholder
Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating and issued a $14.00 price target on shares of Vir Biotechnology in a research report on Monday...
MarketBeat·6d ago
News Placeholder
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average...
MarketBeat·11d ago
News Placeholder
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks PR Newswire VANCOUVER, BC, Jan. 27, 2026...
PR Newswire·19d ago
News Placeholder
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports...
MarketBeat·23d ago
News Placeholder
Vir Biotechnology (NASDAQ:VIR) Shares Up 9.9% - Should You Buy?
Vir Biotechnology (NASDAQ:VIR) Stock Price Up 9.9% - Here's What Happened...
MarketBeat·24d ago
News Placeholder
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta (CHD). Participants receiving...
Business Wire·1mo ago
News Placeholder
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on...
Business Wire·1mo ago
News Placeholder
Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of Vir Biotechnology stock in a transaction that occurred on Friday, January 2nd. The stock was sold at...
MarketBeat·1mo ago
News Placeholder
What is HC Wainwright's Forecast for VIR FY2025 Earnings?
Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Equities researchers at HC Wainwright lifted their FY2025 EPS estimates for shares of Vir Biotechnology in a research note issued on Tuesday...
MarketBeat·1mo ago
<
1
2
...
>

Latest VIR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.